Related Experiment Video
Updated: Apr 6, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
Relationship between serotonin transporter gene polymorphism and constipation in cancer patients
Weiwei Li1, Luli Huang2, Weimei Cai1
1Department of Oncology, the 1 Affiliated Hospital of Xinxiang Medical University, Xinxiang Henan Prov., PR China.
Introduction:
To assess the potential association between serotonin transporter gene insertion/deletion polymorphism and the cancer-related constipation phenotype.
Material And Methods:
A total of 120 patients diagnosed with malignant solid tumors were subjected to genotyping. For the two groups - patients with constipation and constipation-free patients with non-gastrointestinal cancer, 60 cases in each group - we collected the peripheral venous blood. We extracted genomic DNA, and used polymerase chain reaction (PCR) to analyze the serotonin transporter (5-HT) link polymorphic region (5-HTTLPR) polymorphism of the serotonin transporter gene.
Results:
The frequency of S/S genotype in cancer patients with constipation was 66.67% (40/60), and the frequency of the S allele was 79.17% (95/120); the frequency of S/S genotype in cancer patients without constipation was 48.33% (29/60), and the frequency of the S allele was 65.83% (79/120). There was a significant difference between the two groups (p < 0.05).
Conclusions:
The presence of 5-HTTLPRS/S genotype and the S allele in patients with cancers probably carry an increased risk of constipation. However, its role as a cause of cancer-related constipation needs to be further investigated.
More Related Videos
Related Concept Videos
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Drugs for Treatment of Constipation-Predominant IBS
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

